Faruqi & Faruqi, LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company’s stock plunged approximately 40% due to the FDA identifying deficiencies in its New Drug Application for Anaphylm. The deficiencies prevent discussions of labeling and post-marketing requirements, raising concerns about the application’s approvability before the January 31, 2026, PDUFA action date. The firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
AQST INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company’s stock plunged approximately 40% due to the FDA identifying deficiencies in its New Drug Application for Anaphylm. The deficiencies prevent discussions of labeling and post-marketing requirements, raising concerns about the application’s approvability before the January 31, 2026, PDUFA action date. The firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.